Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
202834-92-8
|
| gptkbp:clinicalTrialPhase |
Phase III (terminated)
|
| gptkbp:developedBy |
GlaxoSmithKline
type 1 diabetes Tolerx |
| https://www.w3.org/2000/01/rdf-schema#label |
otelixizumab
|
| gptkbp:macromoleculeType |
gptkb:T-cell_receptor_complex
|
| gptkbp:mechanismOfAction |
immunomodulation
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:source |
humanized (from mouse)
|
| gptkbp:status |
development discontinued
|
| gptkbp:synonym |
TRX4
|
| gptkbp:target |
CD3 receptor
|
| gptkbp:UNII |
6QX8J8QF6H
|
| gptkbp:bfsParent |
gptkb:anti-CD3_antibody
|
| gptkbp:bfsLayer |
7
|